Trial Profile

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Psilocybin (Primary)
Indications Anorexia nervosa
Focus Adverse reactions

Most Recent Events

01 Aug 2023 Results published in the Nature Medicine
25 Jul 2023 According to a COMPASS pathway media release, this study was conducted by Stephanie Knatz Peck at the University of California San Diego School of Medicine.
25 Jul 2023 According to a COMPASS pathway media release, results from this trial were published in the Nature Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com